ANDRÉS JESÚS
MUÑOZ MARTÍN
Profesor asociado de Ciencias de la Salud


Hospital Universitario La Fe
Valencia, EspañaPublications in collaboration with researchers from Hospital Universitario La Fe (10)
2023
-
Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning
Thrombosis Research, Vol. 228, pp. 181-188
2021
-
Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients
Annals of Hematology, Vol. 100, Núm. 4, pp. 1023-1029
2020
-
High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1
European Journal of Cancer, Vol. 141, pp. 193-198
2019
-
Management and supportive treatment of frail patients with metastatic pancreatic cancer
Journal of Geriatric Oncology, Vol. 10, Núm. 3, pp. 398-404
2018
2017
-
Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain
Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681
2016
-
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
British Journal of Cancer, Vol. 115, Núm. 7, pp. 789-796
2015
-
Erratum: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study [Support Care Cancer, DOI 10.1007/s00520-015-2809-3]
Supportive Care in Cancer
-
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
Supportive Care in Cancer, Vol. 23, Núm. 9, pp. 2833-2840
2007
-
Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease
Haematologica, Vol. 92, Núm. 11, pp. 1489-1494